SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy
This study is looking at how well 177Lu-PSMA-617 (Pluvicto) works in men with metastatic castration-resistant prostate carcinoma (prostate cancer that has spread and no longer responds to hormone therapy). Researchers want to see if the amount of medicine absorbed by tumors and normal organs is linked to how well the treatment works and any side effects. You may be able to join if you are a man aged 18 or older, have metastatic castration-resistant prostate carcinoma, and are scheduled to receive 177Lu-PSMA-617 treatment. The study will measure treatment response and side effects for up to 4 years. The current status of this study is unclear, and it plans to enroll 60 participants.
- Study design
- This is an observational study, meaning researchers will watch and collect information without giving you a specific treatment. It plans to include 60 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for up to 4 years to measure treatment response and toxicity.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Yuni K Dewaraja · PRINCIPAL_INVESTIGATOR · University of Michigan Rogel Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Response and toxicity following 177Lu-RLTUp to 4 years
Association between absorbed dose and effect (response/toxicity) following 177Lu-RLT